API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html
https://www.prnewswire.com/news-releases/medivir-presents-data-on-additive-activity-of-fostrox-in-combination-with-lenvima-or-sorafenib-in-non-clinical-tumor-models-at-ilca-301920306.html
https://www.prnewswire.com/news-releases/medivir-reports-promising-interim-data-including-a-first-complete-response-in-phase-1b2a-hcc-study-with-fostrox-in-combination-with-lenvima-301916719.html
https://www.prnewswire.com/news-releases/promising-tumor-control-for-fostrox-in-combination-with-lenvima-in-ongoing-phase-2a-study-in-hcc-15th-patient-included-301899544.html
https://www.pharmaceutical-technology.com/news/chinese-authority-medivir-fostrox/
https://www.prnewswire.com/news-releases/medivir-to-present-data-on-additive-efficacy-of-fostrox-in-triple-combination-with-anti-pd1-and-kinase-inhibitor-in-nonclinical-tumor-models-at-aacr-301774873.html
https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-phase-2a-part-of-medivirs-study-with-fostrox-in-combination-with-lenvima-301771233.html